ABSTRACT To determine whether tissue-type plasminogen activator (t-PA) and urokinase (UK) act synergistically to achieve coronary thrombolysis, incremental doses of both drugs were infused intravenously over 60 min. In 146 consecutive patients treated 3.0 + 1.0 hr from symptom onset, coronary angiography was performed 90 min after the start of the infusion and at 7 days. The groups of patients treated by different dose regimen were as follows: group I, 14 patients treated with t-PA 25 mg and UK 0.5 million U; group II, 20 patients given t-PA 25 mg and UK 1.0 million U; group III, 24 patients given t-PA 1.0 mg/kg and UK 0.5 million U; group IV, 33 patients treated with t-PA 1.0 mg/kg and UK 1.0 million U; and group V, 55 patients given t-PA 1.0 mg/kg and UK 2.0 million U. In groups and II, patency of the infarct-related vessel at 90 min was only 36% and 42%, respectively.
streptokinase, 3 6 9and in one study a 150 mg dose of t-PA, given to achieve rapid and complete recanalization, was associated with an increased incidence of intracranial hemorrhage. 10 The concept of improved efficacy and safety of thrombolysis with the use of synergistic combinations of fibrinolytic agents was recently introduced. [11] [12] [13] [14] Experiments in vitro have not been consistent with regard to whether additivity or synergism exists."1 14 In rabbit and canine preparations, synergism was demonstrated for t-PA and urokinase (UK)12 as well as t-PA and single-chain urokinase-type plasminogen (prourokinase).'2' 15 Preliminary results obtained in small groups of patients with myocardial infarction treated with low-dose combination therapy have also been encouraging. 13 , 16 The primary purpose of the current multicenter trial was to determine whether t-PA and UK act synergistically to achieve coronary thrombolysis. The results obtained in 146 patients were compared with the findings of our previous trial in which 386 patients received t-PA monotherapy.17
Methods
Patient selection. Inclusion criteria were less than 4 hr of chest discomfort with diagnostic electrocardiographic ST segment elevation (>0.1 mV in two or more contiguous leads). Patients with more than 4 but less than 6 hr of symptoms were considered if they had severe, ongoing chest discomfort. Patients were excluded if they were more than 75 years of age, had recent (less than 3 months) trauma, stroke, or major surgery, had previous myocardial damage in the infarct territory, had systolic blood pressure less than 80 mm Hg unresponsive to fluids, or had evidence of recent or active bleeding (e.g., peptic ulcer, hemoptysis). The protocol was approved by the institutional review board at each of the clinical sites. Permission to administer the two investigational fibrinolytic agents concomitantlywas obtained from the Food and Drug Administration. All patients provided informed consent before participation in the study.
Combination fibrinolytic therapy. The predominant single chain form of t-PA (Genentech, Inc., South San Francisco, CA)5' 18 tion, which was more extensive than with t-PA alone (nadir 56 + 73 vs 128 + 78 mg/dl; p = .0001). In agreement with the fibrinogen data, fibrinogen degradation products increased with higher doses of the lytic agents as shown in figure 3 .
Hospital course. Overall, there were five deaths among the 146 patients (3.4%), three of which were among the 112 patients (2.7%) treated with 1 mg/kg t-PA combined with doses of UK (groups III to V). The predischarge status of the infarct vessel is summarized in table 5 .
Discussion
These results do not support the preliminary observations13 that t-PA and UK act synergistically on coronary arterial thrombolysis in patients with acute myocardial infarction. At low doses of both agents representing approximately 25% of the therapeutic dose of each agent, patency rates of the infarct-related vessels were below 45%, which necessitated early termination of patient entry to these groups. With the full therapeutic dose of t-PA (1 mg/kg) and incremental doses of UK (0.5 to 2.0 million U) no further increase in patency rate was observed as compared with our previous experience of t-PA infusion alone. 16 The data thus apparently do not fulfill the Berenbaum criteria for synergism between these thrombolytic agents. 28 The demonstration of 75% patency of the infarctrelated vessel at 90 min of combined high-dose t-PA and UK supports the "plateau" concept for pharmacologic coronary thrombolysis. Prior trials of intracoronary or intravenous thrombolysis with a variety of thrombolytic agents used alone at varying doses have failed to consistently yield patency rates higher than 75%.1-8 The mechanism for resistance in approximately one-fourth of patients is not known, but our findings contradict the possibility of a higher shortterm thrombolytic efficacy. In the present study, the frequency of bleeding complications was surprisingly low, despite the simultaneous use of two thrombolytic agents at high doses and the associated extensive systemic fibrinolytic state.
This observation suggests a few potentially important characteristics of the bleeding associated with fibrinolytic therapy. First, the avoidance of a prolonged t-PA maintenance infusion, which has been observed to predispose to bleeding,31 may be beneficial. Second, the apparent paradox between extensive fibrinogen breakdown and a low frequency of bleeding is reemphasized by the present findings. Finally, with the combined use of full doses of two thrombolytic agents in addition to aspirin and heparin and in the presence of invasive arterial punctures, less than 10% of patients who did not undergo bypass surgery required transfusion, primarily for correction of a decreased hematocrit and not for major clinical bleeding.
The present study has several significant limitations. It represents a sequential experience with relatively small numbers of patients in each group who are compared with the historical controls of the TAMI-I trial. Our present observations therefore need to be verified and extended in a larger prospective, randomized trial.
With limited data in the literature on the effects of intravenous UK therapy36' 37 and the lack of a study group randomized to infusion of UK alone, no firm conclusions can be drawn concerning the relative efficacy of the combination of t-PA and UK as compared with UK alone. Furthermore, in the absence of a pretreatment angiogram and serial early angiographic studies, the current study did not allow us to evaluate the possibility of a synergistic effect of t-PA and UK with respect to the time to recanalization.
In conclusion, we found no evidence for significant synergism between t-PA and UK with respect to coronary artery reperfusion. However, the previously identified high-risk subset27 -patients with persistent occlusion of the infarct-related vessel treated with immediate angioplasty -appeared to benefit from combined t-PA and UK in terms of low reocclusion (4%), low mortality (0%), and improvement of left ventricular function (5.3 point increase in ejection fraction). Since there was no increased bleeding tendency with the combination therapy, the use of UK as an alternative for a prolonged t-PA infusion deserves further prospective evaluation. The 
